
Under the gun with Aduhelm floundering, Biogen sells its stake in biosimilars business for $2.3B
It turns out the Korea Economic Daily was onto something when, over the Christmas break, it reported that Samsung was in the process of making a buyout bid for Biogen. Samsung quickly denied the rumor, and then we heard nothing more on the matter for another month.
Samsung and Biogen broke the news late Thursday that they have indeed been working on a buyout deal — not for the biotech itself, but for its biosimilars joint venture.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,600+ biopharma pros reading Endpoints daily — and it's free.